Fig 1: IDH mutations activate CEBPa-VDR-RXRa axis through 2HG production. (A) RT-qPCR showing gene expressions of VDR and RARA in HL60 IDH1WT (clone 2: ?; clone 7: ?) versus HL60 IDH1R132H (clone 5: ?; clone 11: ?). (B) Western blot showing protein levels of VDR, RXRa and RARa in HL60 IDH1WT (clones 2 and 7) versus HL60 IDH1R132H (clones 5, 11 and 3) (left) and in HL60 IDH2WT versus HL60 IDH2R172K (right). (C) RT-qPCR showing gene expressions of VDR and RARA in 2HG-treated HL60 (200 µM, 1 week). (D) Western blot showing protein levels of VDR RXRa and RARa in 2HG-treated HL60 IDH1WT (clones 2 and 7) (200 µM, 1 week). (E) RT-qPCR showing gene expression of and VDR and RARA in HL60 IDH1WT (clone 2: ?, clone 7: ?) and IDH1R132H (clone 5: ?, clone 11: ?) after CEBPA-KD by shRNA (F) Western blot showing protein levels of CEBPa, VDR, RARa and VDR in HL60 IDH1WT (clones 2 and 7) and IDH1R132H (clone 5 and 11) after CEBPA-KD by shRNA. (G) Western blot showing protein levels of VDR in 2HG-treated HL60 IDH1WT (clone 2 and 7) with CEBPA-KD by shRNA (200 µM, 1 week). The uncropped western blot figures are presented in Figure S6. * p < 0.05; ** p < 0.01.